Accreditation Information

CME

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CEC designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ACGME Competencies

  • Patient care
  • Medical knowledge
  • Systems-based practice

IOM Competencies

  • Work in interdisciplinary teams
  • Employ evidence-based practice

IPE Competencies

  • Roles/ Responsibilities
  • Teams and Teamwork

CPE

This application based activity is approved for 1.00 contact hour (0.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-18-004-L01-P).

CNE

This activity is designated for 1.00 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Other

Creative Educational Concepts, Inc. certifies this activity for 1.00 hour of participation.

Needs Statement

The discovery of actionable mutations in non-small cell lung cancer (NSCLC) and development of biomarker specific targeted therapies have transformed the treatment landscape of advanced NSCLC. The objective of this educational initiative is to provide oncology clinicians with evidence-based information on the latest developments in NSCLC, including updates on biomarker testing and targeted therapeutic options. Practical strategies to improve guideline adherence for molecular testing in the community setting (both at diagnosis and upon disease progression), along with applications of newer testing technologies such as circulating tumor DNA (ctDNA), will be discussed. The importance of developing an interprofessional team approach to effectively diagnosis and manage NSCLC will also be explored.

 

Objectives

  • Review the molecular pathology of advanced non-small cell lung cancer (NSCLC) and identify clinically relevant molecular mutations that impact treatment selection.
  • Examine strategies to coordinate care in the community setting to improve adherence to guideline-recommended molecular testing in NSCLC and discuss the utility of newer technologies such as ctDNA liquid biopsy in clinical practice.
  • Evaluate targeted treatment options for actionable and acquired mutations in NSCLC, such as EGFR/T790M, and assess the safety and efficacy of these targeted therapies.

Using a case-based approach, examine how to best incorporate molecular testing to optimize targeted therapy selection in EGFR-mutated NSCLC at initiation of therapy and upon disease progression.

Target Audience

Members of the interprofessional healthcare team who diagnose and manage patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, physicians’ assistants, nurses, and pharmacists.

Faculty Disclosure

Planner and Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner: 

Adrienne Matson, PharmD, BCPS - has no relevant financial relationships to disclose in relation to the content of this activity.

 

Content Development Faculty:

Dara L. Aisner, MD, PhD - has disclosed that she is a consultant for Abbvie and Bristol-Myers Squibb. She also receives grant/research support form Genetech. 

Leila Rostamnjad, PharmD - has no relevant financial relationships to disclose in relation to the content of this activity.

Lecia V. Sequist, MD, MPH - has disclosed that she is a consultant for  AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Merrimack, Novartis, and Pfizer. 

Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP - has no relevant financial relationships to disclose in relation to the content of this activity.

 

Speaking Faculty:

Joshua Bauml, MD - has disclosed that he is a consultant for AstraZeneca, BMS, Boehringer Ingleheim, Celgene, Clovis, Genentech, Guardant Health, and Merck; his institution receives grant/research support from Bayer, Carevive Systems, Clovis, Janssen, Merck, and Novartis.

Mark G. Kris, MD, FACP, FACCP - has disclosed that he is a consultant for AstraZeneca.

Lecia V. Sequist, MD, MPH - has disclosed that she is a consultant for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Merrimack, Novartis, and Pfizer. 

 

Peer Reviewers:

Josiah D. Land, PharmD - has no relevant financial relationships to disclose in relation to the content of this activity.

Susan H. Scher, MD - has no relevant financial relationships to disclose in relation to the content of this activity.

Elizabeth S. Waxman, RN, MSN, NP-C, AOCN - has no relevant financial relationships to disclose in relation to the content of this activity.